Benzimidazole derivatives are heterocyclic compounds with significant biological activities, including anticancer, antimicrobial, and antiviral effects. Their complexes with versatile metals like ruthenium (Ru) are gaining attention in the field of metallodrugs. Herein, we report on the synthesis and characterization of ruthenium(II/IIII) benzimidazole based complexes namely, K[Ru(BBE)Cl4], [Ru(BBE)2Cl2] and [Ru(2-PC)(BBE)Cl]Cl, [where BBE = 1H-benzo[d]imidazol-2-yl ethane and 2-PC = 4-(4-nitrophenoxy)-N,N-bis(pyridin-2-ylmethyl)aniline]. The synthesized complexes and ligands were characterized using HRESI-MS, 1H-NMR, FTIR, and UV-Vis spectroscopy. Density functional theory (DFT) calculations determined the geometry of the complexes. In vitro studies assessed the anticancer effects on MCF-7 breast cancer cells and evaluated antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, and Klebsiella pneumoniae. Anticancer studies showed that the complexes had a concentration-dependent antiproliferative effect on MCF-7 breast cancer cells, with IC50 values ranging from 59.18-110.90 µM. The anticancer effects were evaluated using in silico molecular docking, which showed that the complexes interact with amino acid residues on the estrogen receptor alpha (ERα). The interaction energies ranged from -7.55 to -9.39 kcal/mol, compared to -6.09 kcal/mol for cisplatin. Antibacterial studies showed that [Ru(BBE)2Cl2] had the highest antibacterial activity against S. aureus and E. faecalis, with inhibition zones of 11 mm and 14 mm, respectively.